Healthcare Webinars

Skin, Healing and Immune Response Chairperson Prof. Andrea R. Genazzani. Speakers: Prof. Frederick Naftolin Estrogens and Skin Prof. Mark Brincat The effects of Hormonal Contraception including COC, And HRT on Collagen turnover.

Join our expert speakers as we discuss birth trauma; the definition, the impacts on physical and mental health, and how to get help.Birth trauma has been hitting the headlines, with thousands of women coming forward to describe the debilitating psychological, physical, and societal impacts of traumatic births on their lives. 30,000 women develop post-traumatic stress disorder (PTSD) every year because of a frightening, stressful or distressing events related to childbirth. Many also find themselves recovering from birth injuries which can be life altering, resulting in chronic pain, incontinence and infertility.Join our expert speakers as we explore this subject in more detail, answering the key questions; What are the main causes of birth trauma? What are the psychological and physical impacts? And most importantly, what support is available for the people affected?Have a question for one of our speakers? Email events@wellbeingofwomen.org.uk before the event and they’ll do their best to answer your questions during the session.

Summary: We identified 71 patients with AdvSM (aggressive SM [ASM], SM with an associated hematologic neoplasm [SM-AHN, e.g., acute myeloid leukemia, SM-AML], mast cell leukemia [MCL]) in two national registries (DRST/GREM) who received an allogeneic hematopoietic cell transplantation (alloHCT) performed in Germany from 1999–2021. Median overall survival (OS) of ASM/SM-AHN (n = 30, 45%), SM-AML (n = 28, 39%) and MCL ± AHN (n = 13, 19%) was 9.0, 3.3 and 0.9 years (P = 0.007). Improved median OS was associated with response of SM (17/41, 41%; HR 0.4 [0.2–0.9], P = 0.035) and/or of AHN (26/43, 60%, HR 0.3 [0.1–0.7], P = 0.004) prior to alloHCT. Adverse predictors for OS included absence of KIT D816V (10/61, 16%, HR 2.9 [1.2–6.5], P < 0.001) and a complex karyotype (9/60, 15%, HR 4.2 [1.8–10.0], P = 0.016). HLA-match, conditioning type or transplantation at centers reporting aboveaverage alloHCTs (≥7) had no impact on OS. Taking into account competing events at years 1, 3 and 5, relapse-related mortality and non-relapse mortality rate were 15%/23%, 20%/30% and 23%/35%, respectively. Irrespective of subtype, subsequent treatment response was achieved in 13/30 (43%) patients and was highest on midostaurin/avapritinib (7/9, 78%). We conclude that outcome of alloHCT in AdvSM is more affected by disease phenotype and treatment response prior to transplant than by transplant characteristics.Speakers: Damaj Gandhi, Laurent Francesco and Onida Andreas Reiter.

In this Webcast, we will confront the critical issue of provider mental health and breaking the silence on topics many avoid. Moving beyond the outdated mindset of "suck it up and move on," we embrace the modern view that it's okay to not be okay. But what happens when you or a colleague truly aren't okay? How do you respond when someone admits they are struggling, considering suicide, or feeling overwhelmed? Have you fostered an environment where such honesty is supported, or are these confessions still trapped, turning colleagues into statistics?Join us as we dive into these uncomfortable but crucial conversations and explore effective resources to effectively support your peers and most importantly yourself.... while earning 1.0 hour of CAPCE-accredited CE. Let's recognize that all of us, despite our Type-A personalities and reliance on caffeine, are human beings in need of support.

Explore how linked electronic health record (EHR) and social drivers of health (SDOH) data are accelerating the identification of health disparities for Type 2 diabetes, Alzheimer’s disease, and heart disease treatments.Through research vignettes highlighting GLP-1s, lecanemab, and TAVR/SAVR procedures, experts from Truveta will demonstrate how complete, clean, and timely regulatory-grade EHR data is shedding light on inequities in therapy access and outcomes. The findings, which rely on linked, patient-level SDOH data, highlight noteworthy variability in treatment patterns based on race, ethnicity, income, familial support, urban/rural status, and more.What you will learn:Learn how clinical expert-led AI is unlocking data hidden within unstructured EHR and SDOH data to enable novel real-world researchDelve into recent studies highlighting trends in real-world use of popular treatmentsGain ideas for leveraging linked EHR and SDOH data to identify and address healthcare disparities

One of the biggest challenges the pharma industry continues to face today is the failure of drug candidates due to unexpected adverse reactions. Late-stage clinical attrition for safety reasons represents a high risk in terms of patient safety and cost. Early anticipation of safety issues enables informed decisions.In this session we will present how OFF-X's analytic tools and curated data from a broad range of sources can help de-risk drug development.Agenda:Challenges the pharma industry continues to face today How the safety intelligence tool OFF-X can help de-risk drug developmentDrug - SemagacestatTarget – BTK inhibitorsTarget- 4-1BB activatorsSummaryQ&ASpeaker: Kinsi Oberoi, Senior Solution Consultant​

Von Hippel-Lindau disease (VHL) is an inherited disorder that predisposes individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, requiring the involvement of genetic counselors and clinicians across the interprofessional team for optimal management.In this webinar, gain expert perspectives from Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, on the following: Varying clinical manifestations of VHL-associated tumors across organ systemsGenetic testing techniques for VHL, including benefits and limitationsEmerging therapies for VHL-associated tumors, including the FDA approval of belzutifanStrategies for conveying genetic information to patients and family membersMultisystemic management of VHL across the interprofessional teamAnd much more! Speaker: Eric Jonasch, MD (Professor, Department of Genitourinary Medical Oncology·University of Texas MD Anderson Cancer Center).

Join us for an exclusive webinar on Advanced Bronchoscopy Coding and Billing 101. Our speakers, Neeraj Desai MD MBA, Joe Cicenia MD, and Otis Rickman DO, will provide valuable insights on how to optimize revenue through proper documentation. This webinar is open to AABIP members only, so register now to secure your spot!

Struggling with back pain? Whether it’s a nagging twinge, persistent throb or a sudden sharpness, you're not alone—80% of the population experiences back pain at some point in their lives. Meet Megan Hill, Doctor of Physical Therapy, your guide to demystifying low back pain. Get practical tips and discover how Thrive, the innovative digital physical therapy program from Sword Health, empowers you to treat and prevent back pain—all from the comfort of home.Agenda:Practical pain-relief tips to prevent low back painCommon back pain mythsHow Thrive WorksLive Q&A with Dr. Megan HillSpeaker: Dr. Megan Hill, PT, DPT (Sword Health).

Educational webinars on rare neurological, neuromuscular and movement disorders jointly organized by the European Reference Networks for Rare Neurological Diseases (ERN-RND) and Neuromuscular Diseases (ERN-EuroNMD) and the European Academy of Neurology (EAN).